Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?

Table 3 Proportion of Days Covered (PDC) among DOAC users by index medication and by any OAC stratified by stroke risk score (CHA₂DS₂-VASc) at 12 months of follow-up

PDC, mean (SD)	Dabigatran (n = 11,650)	Rivaroxaban (n = 10,156)	Apixaban (n = 3486)	P-value
Adherence to index DOAC
Overall	0.57 (0.36)	0.64 (0.36)	0.70 (0.33)
CHA₂DS₂-VASc ≤1	0.44 (0.34)	0.49 (0.35)	0.52 (0.35)	<.0001
CHA₂DS₂-VASc = 2	0.56 (0.35)	0.64 (0.35)	0.68 (0.33)	<.0001
CHA₂DS₂-VASc = 3	0.62 (0.35)	0.69 (0.34)	0.73 (0.32)	<.0001
CHA₂DS₂-VASc ≥4	0.64 (0.35)	0.70 (0.34)	0.76 (0.30)	<.0001
Adherence to any OAC
Overall	0.64 (0.34)	0.68 (0.34)	0.73 (0.31)
CHA₂DS₂-VASc ≤1	0.47 (0.34)	0.52 (0.35)	0.54 (0.36)	<.0001
CHA₂DS₂-VASc = 2	0.62 (0.34)	0.67 (0.34)	0.71 (0.32)	<.0001
CHA₂DS₂-VASc = 3	0.68 (0.33)	0.73 (0.32)	0.77 (0.28)	<.0001
CHA₂DS₂-VASc ≥4	0.72 (0.31)	0.75 (0.31)	0.80 (0.27)	<.0001

ISSN: 1471-2261